The largest South Asian-descent population share in the Americas.

Why Guyana

Guyana is the ancestry story. Just under 40% of the population is of East Indian descent and 29% of African descent, with a further 10.5% Indigenous — a combination found nowhere else in the Western Hemisphere. For cardiometabolic research, where South Asian ancestry carries a distinct phenotype at lower BMI thresholds, that is a scientifically substantive reason to run a cohort here rather than somewhere more convenient.

The disease burden

Guyana's premature NCD mortality is among the worst in the network: a 25.4% probability of dying between 30 and 70 from cardiovascular disease, cancer, diabetes or chronic respiratory disease. Adult obesity shows the region's familiar sex gap — 38.0% in women against 17.2% in men. Diabetes prevalence at 21.1% crude sits high, though on a wide interval reflecting sparse survey input.

Sites and infrastructure

• Georgetown Public Hospital Corporation — a Level V national referral hospital, 558 inpatient beds and cots, 456 doctors, 879 nursing staff, 20 postgraduate programmes
• University of Guyana School of Medicine, Faculty of Health Sciences — a national medical school (MBBS, MPH)
• Texila American University and GreenHeart Medical University — private and international-student institutions

Research heritage

None documented. Published research output is investigator-initiated retrospective work from GPHC and the private universities. There is no established cohort, trial network or research institute. Guyana is a genuinely research-naive environment — which is the point, but it means infrastructure has to come from the network rather than from the country.

Regulatory & ethics

• Government Analyst–Food and Drug Department — has completed a WHO Global Benchmarking Tool assisted self-assessment; a new Medicines Regulation Bill is in development
• Ministry of Health Institutional Review Board, established under the Ministry of Health Act 2005 and its 2007 Regulation — reviews research proposals and grants permission to conduct research in Guyana

The honest position: The national pharmacovigilance system is still being established and medicines legislation is being rewritten. The Ministry of Health IRB is a real, constituted body with a statutory basis — that is the operative approval route, and it is better documented than in most of the Eastern Caribbean. But the regulator has no track record of authorising interventional trials, so timelines should be planned generously.

Data quality: Moderate — population and mortality data are solid, but risk-factor prevalence is modelled with wide intervals indicating few national surveys.

How this site fits the network

Core network site — strong population proposition with a functioning ethics route; research infrastructure developing.

Our Guyana operation is contracted, trained and monitored under the same quality system as our UK and US sites. One master service agreement covers all three regions, one budget negotiation, one set of payment terms. Sites in this network can absorb enrolment from under-recruiting UK or US centres without a new vendor qualification cycle.